Evidence map›Paper›PMID 38168333›Full record

ArticlebioRxiv : the preprint server for biology2023

Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist.

Peter K Um, Monali Praharaj, Kara A Lombardo, Takahiro Yoshida, Andres Matoso, Alex S Baras, Liang Zhao, Geetha Srikrishna, Joy Huang, Pankaj Prasad and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Peter K UmJohns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, USA.
Monali PraharajJohns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, USA.
Kara A LombardoJohns Hopkins University, School of Medicine, Department of Urology, Baltimore, USA.
Takahiro YoshidaDepartment of Urology, Hyogo Prefectural Nishinomiya Hospital, Japan, 6620918.
Andres MatosoDepartment of Pathology, The Johns Hopkins University, Baltimore, USA.
Alex S BarasDepartment of Pathology, The Johns Hopkins University, Baltimore, USA.ORCID 0000-0003-2397-3342
Liang ZhaoThe Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, USA.
Geetha SrikrishnaJohns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, USA.
Joy HuangJohns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, USA.
Pankaj PrasadJohns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, USA.
Max KatesJohns Hopkins University, School of Medicine, Department of Urology, Baltimore, USA.
David McConkeyJohns Hopkins University, School of Medicine, Department of Urology, Baltimore, USA.
Drew M PardollThe Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, USA.
William R BishaiJohns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, USA.ORCID 0000-0002-8734-4118
Trinity J BivalacquaSchool of Medicine, Department of Surgery, University of Pennsylvania, Philadelphia, USA.
Johns Hopkins University · USBloomberg (United States) · USHyogo Prefectural Nishinomiya Hospital · JPUniversity of Pennsylvania · US

Funding

Mycobacterium tuberculosis Survival Regulatory GenesR01AI037856 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BISHAI, WILLIAM RAMSES · 1997 to 2020
$7.2M
A STINGing vaccine for TBR01AI155346 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BISHAI, WILLIAM RAMSES, MEHRA, SMRITI · 2020 to 2024
$4.9M
NIAID NIH HHS R01 AI037856NIAID NIH HHS R01 AI155346
6 · The paper itself

Abstract

Despite the introduction of several new agents for the treatment of bladder cancer (BC), intravesical BCG remains a first line agent for the management of non-muscle invasive bladder cancer. In this study we evaluated the antitumor efficacy in animal models of BC of a recombinant BCG known as BCG-

Identifiers

PMID38168333
PMCPMC10760079
OpenAlexW4389819860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.